Format

Send to

Choose Destination
Gastroenterology. 2018 Oct 18. pii: S0016-5085(18)35162-X. doi: 10.1053/j.gastro.2018.09.058. [Epub ahead of print]

Pathogenesis of and New Therapies for Hepatitis D.

Author information

1
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA. Electronic address: Christopher.Koh@nih.gov.
2
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
3
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA. Electronic address: Jeffrey.glenn@stanford.edu.

Abstract

Hepatitis delta virus (HDV) infection of humans was first reported in 1977, and now it is now estimated that 15-20 million people are infected worldwide. Infection with HDV can be an acute or chronic process that occurs only in patients with an HBV infection. Chronic HDV infection commonly results in the most rapidly progressive form of viral hepatitis; it is the chronic viral infection that is most likely to lead to cirrhosis, and it is associated with an increased risk of hepatocellular carcinoma. HDV infection is the only chronic human hepatitis virus infection without a therapy approved by the Food and Drug Administration. Peginterferon alpha is the only recommended therapy, but it produces unsatisfactory results. We review therapeutic agents in development, designed to disrupt the HDV life cycle, that might benefit patients with this devastating disease.

KEYWORDS:

HCC risk; cancer; drug development; epidemiology

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center